- Home
- A-Z Publications
- Current Neuropharmacology
- Previous Issues
- Volume 19, Issue 7, 2021
Current Neuropharmacology - Volume 19, Issue 7, 2021
Volume 19, Issue 7, 2021
-
-
Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Authors: Sadayuki Hashioka, Zhou Wu and Andis KlegerisThe neuroinflammatory hypothesis of Alzheimer’s disease (AD) was proposed more than 30 years ago. The involvement of the two main types of glial cells microglia and astrocytes, in neuroinflammation, was suggested early on. In this review, we highlight that the exact contributions of reactive glia to AD pathogenesis remain difficult to define, likely due to the heterogeneity of glia populations and alterations in their activ Read More
-
-
-
Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A “Dimmer-Switch” Hypothesis
Authors: Santiago J. Ballaz and Michel BourinCholecystokinin (CCK), the most abundant brain neuropeptide, is involved in relevant behavioral functions like memory, cognition, and reward through its interactions with the opioid and dopaminergic systems in the limbic system. CCK excites neurons by binding two receptors, CCK1 and CCK2, expressed at low and high levels in the brain, respectively. Historically, CCK2 receptors have been related to the induction of pani Read More
-
-
-
Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway
It has been well established that there is a connection between type II diabetes (DMTII) and Alzheimer's disease (AD). In fact, the increase in AD incidence may be an emerging complication of DMTII. Both pathologies are related to estradiol (E2) exposure; on the one hand, estrogen receptors (ER) are emerging as important modulators of glucose homeostasis through ß-pancreatic cell function; on the other hand, brain bioener Read More
-
-
-
Expanding the Arsenal Against Huntington's Disease-Herbal Drugs and Their Nanoformulations
Huntington’s disease (HD) is an autosomal fatal genetic disease in which degeneration of neuronal cells occurs in the central nervous system (CNS). Commonly used therapeutics are cludemonoamine depletors, antipsychotics, antidepressants, and tranquilizers. However, these drugs cannot prevent the psychotic, cognitive, and behavioral dysfunctions associated with HD. In addition to this, their chronic use is limited by their l Read More
-
-
-
Modulation of Gut-Brain Axis by Probiotics: A Promising Anti-depressant Approach
Authors: Koumudhi Rajanala, Nitesh Kumar and Mallikarjuna R. ChamallamudiThe human digestive system is embedded with trillions of microbes of various species and genera. These organisms serve several purposes in the human body and exist in symbiosis with the host. Their major role is involved in the digestion and conversion of food materials into many useful substrates for the human body. Apart from this, the gut microbiota also maintains healthy communication with other body parts, includi Read More
-
-
-
Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Curcumin is a spice derived nutraceutical which gained tremendous attention because of its profound medicinal values. It alters a number of molecular pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF128;ΚB), signal transducer and activator of transcription 3 (STAT3), nuclear factor erythroid 2-related factor 2 (Nrf2) and cyclooxygenases-2 (COX128;2), which make it potential th Read More
-
-
-
SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Neurodegeneration is a complex neurological phenomenon characterized by disturbed coherence in neuronal efflux. Progressive neuronal loss and brain damage due to various age-related pathological hallmarks perturb the behavioral balance and quality of life. Sirtuins have been widely investigated for their neuroprotective role, with SIRT1 being the most contemplated member of the family. SIRT1 exhibits significant cap Read More
-
-
-
C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Neurodegenerative diseases are characterized by the increasing dysfunction and death of neurons, resulting in progressive impairment of a person’s mobility and/or cognition. Protein misfolding and aggregation are commonly hypothesized to cause neurotoxicity and, eventually, neuronal degeneration that are associated with these diseases. Emerging experimental evidence, as well as recent findings from human studies, Read More
-
-
-
Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Authors: Adejoke Y. Onaolapo and Olakunle J. OnaolapoGlutamate’s role as the major excitatory neurotransmitter of the mammalian central nervous system requires that its brain concentrations be kept tightly-controlled. However, in hepatic encephalopathy resulting from liver dysfunction; disruption of central neurotransmission and elevation of brain glutamate levels have been observed. These had been associated with certain neurological changes. While neurological changes r Read More
-
-
-
The Potentials of Uncariae Ramulus Cum Uncis for the Treatment of Migraine: Targeting CGRP in the Trigeminovascular System
Authors: Cheong-Meng Chong, Zhangfeng Zhong, Chi T. Vong, Shengpeng Wang, Jin-Jian Lu, Hai-Jing Zhong, Huanxing Su and Yitao WangMigraine is a common chronic neurovascular disease characterized by headaches. Calcitonin gene-related peptide (CGRP) signaling in the trigeminovascular system plays a critical role in the development of migraine. The monoclonal antibodies against CGRP and its receptor have been used clinically for the prevention of migraine; however, they may not be a cost-effective option for patients with low-frequency episodic Read More
-
-
-
A Systematic Review of the MDMA Model to Address Social Impairment in Autism
Authors: Devahuti Chaliha, John C. Mamo, Matthew Albrecht, Virginie Lam, Ryu Takechi and Mauro VaccarezzaBackground: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterised by repetitive behaviours, cognitive rigidity/inflexibility, and social-affective impairment. Unfortunately, no gold-standard treatments exist to alleviate the core socio-behavioural impairments of ASD. Meanwhile, the prosocial empathogen/entactogen 3,4-methylene-dioxy-methamphetamine (MDMA) is known to en Read More
-
Volumes & issues
-
Volume 23 (2025)
-
Volume 22 (2024)
-
Volume 21 (2023)
-
Volume 20 (2022)
-
Volume 19 (2021)
-
Volume 18 (2020)
-
Volume 17 (2019)
-
Volume 16 (2018)
-
Volume 15 (2017)
-
Volume 14 (2016)
-
Volume 13 (2015)
-
Volume 12 (2014)
-
Volume 11 (2013)
-
Volume 10 (2012)
-
Volume 9 (2011)
-
Volume 8 (2010)
-
Volume 7 (2009)
-
Volume 6 (2008)
-
Volume 5 (2007)
-
Volume 4 (2006)
-
Volume 3 (2005)
-
Volume 2 (2004)
-
Volume 1 (2003)
Most Read This Month
Article
content/journals/cn
Journal
10
5
false
en
